1381 related articles for article (PubMed ID: 23587474)
21. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
22. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
23. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
Shim JH; Lee HC; Han S; Kang HJ; Yu E; Lee SG
Liver Transpl; 2013 Mar; 19(3):336-45. PubMed ID: 23203386
[TBL] [Abstract][Full Text] [Related]
24. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma.
Decaens T; Roudot-Thoraval F; Badran H; Wolf P; Durand F; Adam R; Boillot O; Vanlemmens C; Gugenheim J; Dharancy S; Bernard PH; Boudjema K; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Hilleret MN; Chazouillères O; Cherqui D; Mallat A; Duvoux C
Liver Int; 2011 Jul; 31(6):792-801. PubMed ID: 21645209
[TBL] [Abstract][Full Text] [Related]
25. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation?
De Carlis L; Di Sandro S; Giacomoni A; Slim A; Lauterio A; Mangoni I; Mihaylov P; Pirotta V; Aseni P; Rampoldi A
J Clin Gastroenterol; 2012 Jan; 46(1):78-86. PubMed ID: 21897282
[TBL] [Abstract][Full Text] [Related]
26. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
Kim BK; Kim KA; Park JY; Ahn SH; Chon CY; Han KH; Kim SU; Kim MJ
Eur J Cancer; 2013 Mar; 49(4):826-34. PubMed ID: 22995582
[TBL] [Abstract][Full Text] [Related]
27. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
28. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
29. Milan criteria are useful predictors for favorable outcomes in hepatocellular carcinoma patients undergoing liver transplantation after transarterial chemoembolization.
Kim DY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC; Shin SW; Choo SW; Do YS; Rhee JC
World J Gastroenterol; 2006 Nov; 12(43):6992-7. PubMed ID: 17109521
[TBL] [Abstract][Full Text] [Related]
30. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma.
Manini MA; Sangiovanni A; Martinetti L; Viganò D; La Mura V; Aghemo A; Iavarone M; Crespi S; Nicolini A; Colombo M
Liver Transpl; 2015 Oct; 21(10):1259-69. PubMed ID: 26074360
[TBL] [Abstract][Full Text] [Related]
31. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
32. Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria.
Woo HY; Jang JW; Choi JY; You CR; Jeong SW; Bae SH; Yoon SK; Lee YS; Kim DG
Liver Int; 2008 Sep; 28(8):1120-8. PubMed ID: 18492023
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of hepatic resection and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria].
Guo Z; Xiang B; Zhang J; Jiang J; Li L
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1526-9. PubMed ID: 25146737
[TBL] [Abstract][Full Text] [Related]
34. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma.
Tsochatzis E; Garcovich M; Marelli L; Papastergiou V; Fatourou E; Rodriguez-Peralvarez ML; Germani G; Davies N; Yu D; Luong TV; Dhillon AP; Thorburn D; Patch D; O'Beirne J; Meyer T; Burroughs AK
Liver Int; 2013 Jul; 33(6):944-9. PubMed ID: 23530918
[TBL] [Abstract][Full Text] [Related]
35. Appropriate treatment strategies for intrahepatic recurrence after curative resection of hepatocellular carcinoma initially within the Milan criteria: according to the recurrence pattern.
Zhang X; Li C; Wen T; Yan L; Li B; Yang J; Wang W; Xu M; Lu W; Jiang L
Eur J Gastroenterol Hepatol; 2015 Aug; 27(8):933-40. PubMed ID: 25933127
[TBL] [Abstract][Full Text] [Related]
36. Poor prognosis for hepatocellular carcinoma with transarterial chemoembolization pre-transplantation: retrospective analysis.
Li HL; Ji WB; Zhao R; Duan WD; Chen YW; Wang XQ; Yu Q; Luo Y; Dong JH
World J Gastroenterol; 2015 Mar; 21(12):3599-606. PubMed ID: 25834326
[TBL] [Abstract][Full Text] [Related]
37. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients.
Ataide EC; Boin IF; Almeida JR; Sevá-Pereira T; Stucchi RS; Cardoso AR; Caruy CA; Escanhoela CA
Transplant Proc; 2011 May; 43(4):1362-4. PubMed ID: 21620130
[TBL] [Abstract][Full Text] [Related]
39. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.
Graziadei IW; Sandmueller H; Waldenberger P; Koenigsrainer A; Nachbaur K; Jaschke W; Margreiter R; Vogel W
Liver Transpl; 2003 Jun; 9(6):557-63. PubMed ID: 12783395
[TBL] [Abstract][Full Text] [Related]
40. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
